Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.
Douglas Love, Annexon’s president and chief executive officer, said the company is focused on “the next generation of complement therapies” for neuroinflammatory diseases by targeting C1q, which he described as the initiator of the classical complement pathway. Love said the company’s approach is differentiated from downstream complement targets such as C3 and C5.
